These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1796300)
21. [Contribution of biology to the therapeutic decision: cancer of the breast in 1995]. Chinot O; Romain S; Martin PM Bull Cancer Radiother; 1995; 82(2):225-37. PubMed ID: 7546893 [No Abstract] [Full Text] [Related]
22. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993 [TBL] [Abstract][Full Text] [Related]
23. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors. Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047 [TBL] [Abstract][Full Text] [Related]
24. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758 [TBL] [Abstract][Full Text] [Related]
25. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. Sirén V; Peltonen J; Vaheri A Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192 [TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678 [TBL] [Abstract][Full Text] [Related]
27. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]. Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198 [TBL] [Abstract][Full Text] [Related]
28. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943 [TBL] [Abstract][Full Text] [Related]
29. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay. Reilly D; Andreasen PA; Duffy MJ Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998 [TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Ganesh S; Sier CF; Griffioen G; Vloedgraven HJ; de Boer A; Welvaart K; van de Velde CJ; van Krieken JH; Verheijen JH; Lamers CB Cancer Res; 1994 Aug; 54(15):4065-71. PubMed ID: 8033138 [TBL] [Abstract][Full Text] [Related]
32. Occurrence of components of fibrinolysis pathways in situ in neoplastic and nonneoplastic human breast tissue. Costantini V; Zacharski LR; Memoli VA; Kudryk BJ; Rousseau SM; Stump DC Cancer Res; 1991 Jan; 51(1):354-8. PubMed ID: 1846311 [TBL] [Abstract][Full Text] [Related]
33. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Duffy MJ; Reilly D; O'Sullivan C; O'Higgins N; Fennelly JJ; Andreasen P Cancer Res; 1990 Nov; 50(21):6827-9. PubMed ID: 2119883 [TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Foekens JA; Buessecker F; Peters HA; Krainick U; van Putten WL; Look MP; Klijn JG; Kramer MD Cancer Res; 1995 Apr; 55(7):1423-7. PubMed ID: 7882345 [TBL] [Abstract][Full Text] [Related]
35. Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer. Wojtukiewicz MZ; Sierko E; Zacharski LR; Rózanska-Kudelska M; Zimnoch L Semin Thromb Hemost; 2003 Jun; 29(3):317-20. PubMed ID: 12888936 [TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104 [TBL] [Abstract][Full Text] [Related]
37. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Koelbl H; Kirchheimer JC; Tatra G; Christ G; Binder BR Obstet Gynecol; 1988 Aug; 72(2):252-6. PubMed ID: 3134631 [TBL] [Abstract][Full Text] [Related]
38. Factors involved in the plasminogen activation system in human breast tumours. Damjanovich L; Turzó C; Adány R Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332 [TBL] [Abstract][Full Text] [Related]
39. Comparative prognostic value of Cathepsin D and urokinase plasminogen activator, detected by immunohistochemistry, in primary breast carcinoma. Göhring UJ; Scharl A; Thelen U; Ahr A; Crombach G Anticancer Res; 1996; 16(2):1011-8. PubMed ID: 8687092 [TBL] [Abstract][Full Text] [Related]
40. Urokinase-type plasminogen activator and its inhibitor PAI-1 in breast cancer: studies at both protein and mRNA level. Reilly D; Andreasen P; Duffy MJ Biochem Soc Trans; 1991 Feb; 19(1):44S. PubMed ID: 1903741 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]